
Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.
Supplements and Featured Publications
almost 26 years ago
Participating Facultyalmost 26 years ago
Introductionalmost 26 years ago
Clinical Choices of Antibiotics: Judging Judicious Usealmost 26 years ago
Is Drug Resistance Affecting Treatment Outcomes?almost 26 years ago
Guidelines for the Management of Community-Acquired Pneumoniaalmost 26 years ago
Optimizing the Use of Antimicrobial Therapyalmost 26 years ago
Selected Abstracts




